Rigel Pharmaceuticals Third Quarter 2024 Earnings Beats Expectations Rigel Pharmaceuticals Third Quarter 2024 Results Key Financial Results Revenue US55.3m up 97 percent from...

Rigel Pharmaceuticals Third Quarter 2024 Earnings Beats Expectations

RIGL Stock  USD 18.95  0.78  3.95%   
About 66% of Rigel Pharmaceuticals' investor base is looking to short. The analysis of the overall investor sentiment regarding Rigel Pharmaceuticals suggests that many traders are alarmed. Rigel Pharmaceuticals' investing sentiment shows overall attitude of investors towards Rigel Pharmaceuticals.
Rigel Pharmaceuticals Third Quarter 2024 Results Key Financial Results Revenue US55.3m up 97 percent from...

Read at simplywall.st
Simply Wall St News at Macroaxis
  

Rigel Pharmaceuticals Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Rigel Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Rigel Pharmaceuticals Maximum Pain Price Across July 18th 2025 Option Contracts

Rigel Pharmaceuticals' options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of Rigel Pharmaceuticals close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of Rigel Pharmaceuticals' options.

Rigel Pharmaceuticals Fundamental Analysis

We analyze Rigel Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Rigel Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Rigel Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Working Capital

Working Capital Comparative Analysis

Rigel Pharmaceuticals is currently under evaluation in working capital category among its peers. Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .

Rigel Pharmaceuticals Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Rigel Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Rigel Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Rigel Pharmaceuticals by comparing valuation metrics with similar companies.

Peers

Rigel Pharmaceuticals Related Equities

ENVBEnveric Biosciences   5.79   
0%
33.0%
FBIOFortress Biotech   2.89   
0%
16.0%
LPTXLeap Therapeutics   2.78   
0%
15.0%
TERNTerns Pharmaceuticals   2.72   
0%
15.0%
INZYInozyme Pharma   0.25   
0%
1.0%
DAWNDay One   0.32   
1.0%
0%
ABOSAcumen Pharmaceuticals   0.97   
5.0%
0%
MREOMereo BioPharma   1.75   
10.0%
0%
RVPHReviva Pharmaceuticals   1.90   
10.0%
0%
ZURAZura Bio   1.92   
11.0%
0%
CDTXCidara Therapeutics   2.10   
12.0%
0%
ELEVElevation Oncology   3.03   
17.0%
0%
XFORX4 Pharmaceuticals   4.02   
23.0%
0%
IMMXImmix Biopharma   17.43   
100.0%
0%
When determining whether Rigel Pharmaceuticals is a strong investment it is important to analyze Rigel Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Rigel Pharmaceuticals' future performance. For an informed investment choice regarding Rigel Stock, refer to the following important reports:
Check out Rigel Pharmaceuticals Hype Analysis, Rigel Pharmaceuticals Correlation and Rigel Pharmaceuticals Performance.
For more information on how to buy Rigel Stock please use our How to buy in Rigel Stock guide.
You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Rigel Pharmaceuticals. If investors know Rigel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Rigel Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
17.867
Earnings Share
2.09
Revenue Per Share
11.505
Quarterly Revenue Growth
0.806
Return On Assets
0.1815
The market value of Rigel Pharmaceuticals is measured differently than its book value, which is the value of Rigel that is recorded on the company's balance sheet. Investors also form their own opinion of Rigel Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Rigel Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Rigel Pharmaceuticals' market value can be influenced by many factors that don't directly affect Rigel Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Rigel Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Rigel Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Rigel Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.